bluebird bio (NASDAQ:BLUE) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report released on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Other research analysts also recently issued reports about the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $80.00 target price on shares of bluebird bio in a research report on Friday, November 15th. Baird R W downgraded shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Wells Fargo & Company decreased their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating for the company in a research note on Monday, February 24th. Finally, Bank of America cut shares of bluebird bio from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $48.10.

bluebird bio Trading Up 2.8 %

Shares of NASDAQ:BLUE opened at $4.11 on Tuesday. bluebird bio has a 52 week low of $3.56 and a 52 week high of $33.20. The company’s 50 day moving average is $7.02 and its two-hundred day moving average is $8.72. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. The company has a market cap of $39.96 million, a PE ratio of -0.11 and a beta of 0.76.

Institutional Trading of bluebird bio

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of bluebird bio in the fourth quarter valued at about $175,000. State Street Corp boosted its holdings in shares of bluebird bio by 1.1% in the third quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 43,382 shares in the last quarter. Captrust Financial Advisors boosted its holdings in shares of bluebird bio by 48.2% in the third quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 77,293 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of bluebird bio in the third quarter valued at about $42,000. Finally, Geode Capital Management LLC boosted its holdings in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after acquiring an additional 166,771 shares in the last quarter. Hedge funds and other institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.